PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of actamyolLink to Publisher's site
 
Acta Myol. 2011 December; 30(3): 202–203.
PMCID: PMC3298106

S1.4 Cardiovascular involvement in Pompe disease

The heart is part of the clinical phenotype of Glycogen storage disease type II (GDS II; Pompe disease; or acid maltase deficiency) since its original description. In 1932, Johannes Pompe, a Dutch pathologist, described the case of a 7-month old infant who died suddenly for a severe idiopathic hypertrophy of the heart (1). Although other cases of massive hypertrophy of the heart have previously been described, Dr. Pompe first demonstrated that not only the heart was involved, but also other organs showed a vacuolar storage of glycogen ("cardiomegalia glycogenica") (1). From a cardiologist's point of view, Pompe disease is one of the leading cause of familial (idiopathic) hypertrophic cardiomyopathy in neonatal and paediatric age (2). GSD II is broadly divided into two onset forms based on the age symptoms occur.

Infantile onset ("Classic" Form)

In the classic infantile form (Pompe disease), cardiomyopathy and conduction disorders, along with muscular hypotonia ("floppy baby"), macroglossia, and organomegalia, are the cardinal features.

Cardiomyopathy is generally of the hypertrophic type, demonstrating a severe thickening of the septum ("asymmetric" hypertrophy), or frequently of both the septum and free walls of the left and right heart ("concentric" hypertrophy). When the septal hypertrophy is very pronounced, a left outflow tract obstruction (favoured by a systolic anterior motion of the anterior mitral leaflet) may be present to worsen the disease (about 30% of the cases). Both diastolic and systolic dysfunction can be observed. Levine JC et al. showed a rapid regression of left ventricular hypertrophy in response to enzyme replacement therapy (ERT) in most of the patients, and systolic ventricular function was preserved despite rapid changes in ventricular mass and size (3).

Glycogen storage involves not only cardiac myocytes, but also the special cells of the conduction system (particularly, the A-V node and the His-bundle cells), representing the hystological background of classical electrocardiographic abnormalities in Pompe disease: pre-excitation patterns (short PR, delta waves), atrio-ventricular blocks and bundle branch abnormalities. The pathogenesis of ventricular pre-excitation (Wolf Parkinson White syndrome, WPW, when symptomatic) is unknown, though is clear that the pattern does not reflect the presence of an accessory pathway (as in the classic WPW) (4). The suggested hypothesis are: a) a "direct insulating effect" of the glycogen on the conduction system; b) an "indirect insulating effect" of the glycogen on the conduction system, by the anatomic interruption of the annulus fibrosus (which acts as an "electric insulate" between the atria and the ventricles (4).

Differential diagnosis

A metabolic or mitochondrial cardiomyopathy may mimic the presentation of GDSII cardiomyopathy (5). The presence of encephalomyopathy, metabolic acidosis (with or without hypoglycemia), the increase of lactate and lactate/piruvate ratio (normal: < 15:1; abnormal: 25:1) may suggest a mitochondrial cardiomyopathy. Hypoglycemia, with or without variation of plasma ketones, insulin, free fatty acids or carnitine may represent an hallmark of metabolic cardiomyopathies (i.e. beta oxidation deficits).

Infantile onset ("Non Classic" Form)

Compared to the classic form, the onset of the "non classic form" of Pompe disease is generally after the first year of age, with a less severe picture, including muscle weakness, cardiomyopathy, and sometimes macroglossia and organomegalia.

Conduction abnormalities and ECG signs of ventricular hypertrophy are generally part of the disease spectrum. Echocardiographic appearance of cardiac hypertrophy is generally less severe and progressive, lacking the left ventricular obstruction and the systolic dysfunction that significantly worsen the classic phenotype. However, the clinical presentation may be extremely various, as demonstrated by Suzuki et al. (6), which reported on a male who developed cardiomyopathy at 12 years of age and died of heart failure at age 15 years without any clinical and/or histological sign of skeletal myopathy.

Differential diagnosis

On the cardiology point of view, the differential diagnosis is with overlapping phenotypes, including syndromic, mitochondrial or metabolic cardiomyopathies (5). Ventricular pre-excitation on the ECG and the presence of idiopathic left ventricular hypertrophy in children are common feature of storage diseases (AMPkinase disease, Danon disease), and mitochondrial disorders (MELAS, MERFF). Particularly, Danon disease is an X-linked glycogen storage disorder due to the absence of the LAMP-2, lysosome- associated membrane protein 2 (evidenced by Immunohistochemistry or by genetic sequencing). Compared with Pompe disease, cognitive impairment and retinitis pigmentosa may be distinctive features of the diseases.

Adult Onset

Adult-onset acid maltase deficiency may simulate limb-girdle dystrophy and the heart may represent a rare finding. Nevertheless, the cardiac phenotype of adults with GDSII is poorly characterized, so far.

Descriptions of heart abnormalities in adults with Pompe disease are sparse. Recently, a relatively large cohort of adults (87 patients, median age 44 years old, 51% males) with Pompe disease have been evaluated (7). A short PR interval was present in 10%, 7% showed a decreased left ventricular systolic function, and 5% had elevated left ventricular mass on echocardiogram. No change in cardiovascular status associated with enzyme replacement therapy (ERT) was observed.

Severe vacuolization of vascular smooth muscle with accumulation of glycogen, particularly involving large and small cerebral arteries with aneurysm formation, have previously been reported (8, 9). Gungor D et al. (10) described survival of 268 patients with Pompe diseases, collected in a prospective international observational study conducted between 2002 and 2009. Out of 34 deaths reported, the cause of death was recognized in 9 patients, including 1 patient who died for aortic dissection. The evidence of smooth muscle involvement seem to be confirmed by the finding of an increased aortic stiffness in adults with Pompe disease (11), which may be due to glycogen storage in the vessel wall, causing reduced vascular elasticity. These findings deserve future investigations.

SUMMARY CLINICAL SYNOPSIS

Principal investigations:

  • ECG: short PR (WPW syndrome), signs of left ventricular hypertrophy with repolarization abnormalities, Atrioventricular and/or intraventricular conduction delays.
  • Echo: left ventricular hypertrophy (or, biventricular hypertrophy), with or without: a) left ventricular outflow tract obstruction (about 30%); b) systolic dysfunction; c) diastolic dysfunction (generally, present).

Other investigations:

  • 24 hours ECG Holter: intermittent WPW and/or conduction delays.
  • Functional capacity study: by six minute walking test and/or cardiopulmonary exercise test.
  • Cardiac Magnetic Resonance Imaging (CMRI), with late gadolinueum analysis: to study cardiac morphology and function, and to determinate a non invasive, "texture characterization" of the cardiac muscle.

References

1. Pompe JC. Over idiopathische hypertrophie van het hart. Ned Tijdschr Geneeskd. 1932;76:304–312.
2. Elliott P, Andersson B, Arbustini E, et al. Classification of the cardiomyopathies: a position statement from the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2008;29:270–276. [PubMed]
3. Levine JC, Kishnani PS, Chen YT, et al. Cardiac remodeling after enzyme replacement therapy with acid alpha-glucosidase for infants with Pompe disease. Pediatr Cardiol. 2008;29:1033–1042. [PMC free article] [PubMed]
4. Arad M, Moskowitz IP, Patel VV, et al. Transgenic mice overexpressing mutant PRKAG2 define the cause of Wolff-Parkinson- White syndrome in glycogen storage cardiomyopathy. Circulation. 2003;107:2850–2856. [PubMed]
5. Limongelli G, Elliott PM. Oxford Texbook of Heart Failure. Oxford Univeristy Press; 2011. The genetics of heart failure.
6. Suzuki Y, Tsuji A, Omura K, et al. Km mutant of acid alpha-glucosidase in a case of cardiomyopathy without signs of skeletal muscle involvement. Clin Genet. 1988;33:376–385. [PubMed]
7. Forsha D, Li JS, Smith PB, et al. Late Onset Treatment Study Investigators, investigators. Cardiovascular abnormalities in late onset Pompe disease and response to enzyme replacement therapy. Genet Med. 2011;13:625–631. [PMC free article] [PubMed]
8. Makos MM, McComb RD, Hart MN, et al. Alpha-glucosidase deficiency and basilar artery aneurysm: report of a sibship. Ann Neurol. 1987;22:629–633. [PubMed]
9. Kretzschmar HA, Wagner H, Hübner G, et al. Aneurysms and vacuolar degeneration of cerebral arteries in late-onset acid maltase deficiency. J Neurol Sci. 1990;98:169–183. [PubMed]
10. Güngör D, Vries JM, Hop WC, et al. Survival and associated factors in 268 adults with Pompe disease prior to treatment with enzyme replacement therapy. Orphanet J Rare Dis. 2011;1:6–34. [PMC free article] [PubMed]
11. Nemes A, Soliman OI, Geleijnse ML, et al. Increased aortic stiffness in glycogenosis type 2 (Pompe's disease) Int J Card. 2007;120:138–141. [PubMed]

Articles from Acta Myologica are provided here courtesy of Pacini Editore